Cartesian Therapeutics Future Growth
Future criteria checks 2/6
Cartesian Therapeutics is forecast to grow earnings and revenue by 6.1% and 22.7% per annum respectively while EPS is expected to grow by 60.4% per annum.
Key information
6.1%
Earnings growth rate
60.4%
EPS growth rate
Biotechs earnings growth | 24.8% |
Revenue growth rate | 22.7% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 09 May 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -122 | -49 | N/A | 2 |
12/31/2025 | N/A | -73 | -39 | -47 | 3 |
12/31/2024 | 6 | -100 | -21 | -30 | 3 |
3/31/2024 | 26 | -292 | -59 | -58 | N/A |
12/31/2023 | 26 | -257 | -51 | -51 | N/A |
9/30/2023 | 0 | -9 | -8 | -8 | N/A |
12/31/2022 | 111 | 35 | -33 | -32 | N/A |
12/31/2021 | 85 | -26 | -61 | -60 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RNAC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RNAC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RNAC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RNAC's revenue (22.7% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: RNAC's revenue (22.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if RNAC's Return on Equity is forecast to be high in 3 years time